FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* LARANJEIRA CHARLES ANTHONY						Pacira BioSciences, Inc. [PCRX]										ck all applic	ationship of Reporting		son(s) to Iss 10% Ov Other (s	vner
(Last) (First) (Middle) C/O PACIRA BIOSCIENCES, INC. 5 SYLVAN WAY, SUITE 300					3. Date of Earliest Transaction (Month/Day/Year) 08/03/2020										X	below) below) SVP, Technical Operations				,
(Street) PARSIPPANY NJ 07054 (City) (State) (Zip)					4. If Amendment, Date of Original Filed (Month/Day/Year)										6. Ind Line)					
		Tab	le I - Nor	n-Deriv	ative	Sec	uriti	ies Ac	quire	l, Di	spose	d of	f, or Be	nefic	ially	Owned	i			
				2. Transaction Date (Month/Day/Ye		Execution Date		3. Transaction Code (Instr. 8)		n Dispo	4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 5)			4 and Securit		es ally Following	Forn (D) o	n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									Cod	v	Amo	ınt	(A) or (D)	Pric	ce	Transac (Instr. 3	ction(s)			(instr. 4)
Common Stock 08/0					/2020	2020			M ⁽¹		2,	500	A	\$	44.1	22	,750		D	
Common Stock 08/03/					/2020	2020			S ⁽¹⁾	S ⁽¹⁾		2,500		D \$52		B 20,796 ⁽²⁾			D	
		7	able II -										or Ben ole secu			Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Da	Date,	4. Transac Code (II 8)		n of l		Expirati	6. Date Exercisal Expiration Date (Month/Day/Year			7. Title and Amount of Securities Underlying Derivative Secur (Instr. 3 and 4)		100	3. Price of Derivative Security Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership t (Instr. 4)
					Code	v	(A)	(D)	Date Exercis	able	Expiration		Title	Amou or Numb of Share	oer					
Common Stock	\$44.1	08/03/2020			M			2,500	(3)		06/02/20	27	Common Stock	2,50	00	\$0.00	7,500		D	

Explanation of Responses:

- 1. The option exercise and sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
- $2. \ Includes \ 546 \ shares \ of \ common \ stock \ acquired \ under \ the \ issuer's \ employee \ stock \ purchase \ plan \ in \ June \ 2020.$
- 3. The stock option vests and becomes exercisable as to 25% of the option shares on May 1, 2018, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.

Remarks:

/s/ Kristen Williams, Attorney-

08/05/2020

in-Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.